{'fraction_non_alphanumeric': 0.02635431918008785, 'fraction_numerical': 0.0014641288433382138, 'mean_word_length': 5.452830188679245, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Angiotensin receptor blockers and risk of cancer].

Angiotensin receptor blockers (ARBs) are a commonly used medication to treat hypertension, heart failure and renal disease, with millions of patients treated with these medications world-wide. The ARBs have been extensively studied in cardiovascular and renal outcome trials and have been found to have broadly similar efficacy to angiotensin converting enzyme inhibitors (ACE-inhibitors) at preventing cardiovascular and renal events but with the advantage of better tolerability. Consequently, current guidance in the U.K. recommends the use of ARBs for the treatment of hypertension in patients intolerant of ACE-inhibitors 1 .